Singapore’s first FDA approval for novel drug

MerLion Pharmaceuticals, a joint venture between the Institute of Molecular and Cell Biology (IMCB) and GlaxoSmithKline, received the first FDA approval for a novel drug amongst the outstanding biotechs based in Singapore. MerLion’s finafloxacin was acquired after its merger withCombinature Biopharm AG and Athelas SA in 2006, and is targeted for acute otitis externa (also known as “swimmer’s ear”). Thanks …

Singapore, meetup

Biomedical Sciences industry in Singapore: Landscape & Trends

The Biomedical Sciences (BMS) industry was identified as the fourth pillar of Singapore’s economy in 2000. To date, Singapore has become a hub in Asia for cutting research in BMS as well as for development of biotechnology & medical technology products. The manufacturing of pharmaceuticals, biotechnology & medical technology products by more than 100 companies exceed S$30 billion each year; …

Download: How Singapore’s pharma companies and government are achieving energy efficiency

  Click here to download this presentation > Earlier this year at the BioPharma Asia convention,  the Energy & Utility Manager for GlaxoSmithKline, Singapore delivered the presentation: The collaborative approach by Singapore's pharmaceutical companies and government agencies to achieve the national aspiration for energy efficiency The contents for this presentation: Utilities Work stream Good Practices Sharing Projects Replicated Energy savings …

PRA Opens Office in Singapore, Centralized Operations to Enhance Regional Presence

New office will serve as PRA's central clinical operations location for the region, strengthening the quality and timeliness of our deliverables to sponsors. Contributed by PRA: PRA, a leading Clinical Research Organization, continues our expansion across the burgeoning Asia-Pacific region with the recent opening of an office in Singapore. The Singapore facility, conveniently located in the heart of the city-state, …